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Abstract
Assisted reproductive technologies (ART) represent commonly utilized management strategies for infertility with multifactorial
causes (including genetically predisposed diseases). Amongst ART, in vitro fertilization (IVF) is the most popular. IVF treatment
may predispose the mother to increased risks and complications during pregnancy, and there may be adverse fetal outcomes.
Hormonal therapies, including oral contraceptives, may impair glucose and lipid metabolism, and promote insulin resistance and
inflammation. IVF treatment involves administration of reproductive hormones, similar in composition but in much higher doses
than those used for oral contraception. The provision of IVF reproductive hormones to mice associates with glucose intolerance.
In addition, the physiological and hormonal changes of pregnancy can trigger an inflammatory response, and metabolic and
endocrine changes. There is controversy regarding the potential effects of IVF hormonal therapies in the promotion of diabeto-
genic and inflammatory states, additional to those that occur during pregnancy, and which may therefore predispose women with
IVF-conceived pregnancies to adverse obstetric outcomes compared with women with spontaneously conceived pregnancies.
This review summarizes the limited published evidence regarding the effect of IVF-based fertility therapies on glucose homeo-
stasis, insulin resistance, cardio-metabolic profile, and markers of inflammation.
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Abbreviation
ART Assisted reproductive technologies
IVF In vitro fertilization
GDM Gestational diabetes mellitus
LBP Lipopolysaccharide-binding protein
Introduction
Infertility is a global health concern and affects 20% of couples
of reproductive age. The use of assisted reproductive technolo-
gies (ART), including primarily in vitro fertilization (IVF), is
becoming more prevalent. Oral contraceptive hormones com-
monly associate with gastrointestinal side effects from changes
in gut microflora, in addition to possible adverse effects on
glucose and lipid metabolism, which in turn may promote in-
sulin resistance and inflammation. The concentration of repro-
ductive hormones is much higher when used for IVF than oral
contraception. However, confirmation of the safety of IVF
(both maternal and fetal) remains tenuous. Previous studies
have focusedmainly on risk of obstetric complications and fetal
outcomes in IVF-conceived pregnancies, with relatively few
studies investigating the possible effects of IVF hormones on
maternal metabolic, endocrine and inflammatory status, and the
relationship to the known diabetogenic and atherogenic effects
of pregnancy. Regarding the inflammatory response, the intes-
tinal microbiota is of particular interest, given its central role in
the modulation of immune-regulation (including during preg-
nancy), and insulin sensitivity. It would be desirable to have
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reliable predictive factors for possible metabolic, endocrine,
and inflammatory sequelae of IVF therapies. Such factors could
help prevent, or at least identify, at an early stage potential
maternal and/or fetal complications, such as onset of gestational
diabetes. In this brief review, we outline existing literature re-
garding the potential adverse maternal and fetal outcomes of
exogenously administered reproductive hormones (oral contra-
ception and IVF) on glucose and insulin homeostasis, metabol-
ic profile, and inflammatory status.
Infertility
Infertility is defined as the “inability to conceive after
12 months of unprotected intercourse, and 6 months for wom-
en 35 years of age and older” [1]. Globally, 15–20% of cou-
ples are infertile, and this corresponds to 35% female infertil-
ity, 30%male infertility, and 20% combination of the two, and
the remaining 15% of cases corresponds to idiopathic or un-
explained infertility [2, 3].
Many factors are associated with infertility in women.
Mechanical impairment of the reproductive system accounts
for about 35% of female infertility and includes damaged or
blocked fallopian tubes, fibroids, and endometriosis. Age has a
significant impact on female fertility, affecting both quality and
quantity of eggs: reproductive age peaks in the 20s and early
30s and starts to decline after the age of 35 years [1]. Ovulation
and hormonal-related disturbances are common causes of fe-
male infertility. Polycystic ovary syndrome (PCOS) is the most
common endocrine disorder in women of reproductive age and
is associated with obesity, hyperinsulinemia, and insulin resis-
tance [4]. Although frequently co-existent with PCOS, there is
evidence to support the notion that overweight and obesity are
independent contributors to female infertility, mediated through
adverse effects on reproductive hormones, manifesting as
anovulation [5]. Thyroid dysfunction is also a common endo-
crine disorder to impair menstrual cyclicity and female fertility
[6]. In men, fertility is adversely affected by advanced age,
smoking, and obesity, similar to women, although age-related
effects are less pronounced, with fertility only declining in men
after the age of 50 years [7].
Obstetric risks and complication of IVF
therapies
Risks of IVF treatment on maternal outcomes
Despite a steady increase in the medical treatment of infertility
with ART, there is still a lack of published evidence on their
safety. Compared with other ART treatments, IVF treatment pre-
disposes to increased maternal risks and complications, since
there is alteration of the normal physiological development of
pregnancy during IVF. Furthermore, use of stimulating agents
can also adversely affect pregnancy outcome, including associa-
tion with ovarian cysts, ovarian enlargement, and ovarian hyper
stimulation syndrome (OHSS) [3]. Ectopic pregnancy is twice as
common, and pregnancy loss after 12 weeks is more prevalent
with IVF-conceived pregnancies [8]. Furthermore,multiple preg-
nancies account for 25% of IVF-conceived pregnancies [9].
However, although twin and triplet pregnancies have a higher
complication rate overall compared with singleton ones (includ-
ing preeclampsia, gestational diabetesmellitus (GDM), thrombo-
embolism, and preterm delivery), complication rates overall are
similar between IVF-conceived and spontaneously conceived
pregnancies [10, 11]. Future studies should focus on obstetric
outcomeswith IVF-conceived pregnancies in larger cohorts, well
matched with spontaneous pregnancies, including those that re-
sult in multiple pregnancies.
One reason for higher rates of maternal adverse outcomes
with IVF may relate to the frequent categorization of women
undergoing IVF as “high risk,” as they usually present with
advanced age, high BMI (> 30 kg/m2), or a pre-existing medi-
cal condition such as PCOS [12]. A higher prevalence of spon-
taneous abortion occurs in IVF-conceived pregnancies in wom-
enwho are also obese and/or have a history of PCOS [13]. IVF-
conceived pregnancy is a “high-risk” intervention with in-
creased risk for maternal and obstetric complications. These
include miscarriage, vaginal bleeding, frequent hospitalization,
GDM, gestational hypertension, and preterm labor [14, 15].
However, there is some controversy in the literature regarding
the actual risk of adverse obstetric and maternal outcomes with
IVF: in a large retrospective study by Kozinszky et al. [10], data
did not show increased rates of obstetric complications with
IVF-conceived pregnancy. Cesarean section is more common
with IVF. Women may consider IVF-conceived pregnancy as
“precious” after many years of infertility and choose cesarean
section to prevent perceived complications from a natural de-
livery, and not necessarily because of medical necessity [16].
Compared with spontaneously conceived pregnancy, women
with IVF-pregnancies are more likely to develop GDM. This
association remains following adjustment for maternal and ges-
tational age, and parity [17]. It is possible that the increased risk
for GDM in IVF-conceived pregnancies may stem from asso-
ciation with prenatal obesity or maternal PCOS (conditions that
are not always specified) [18]. Furthermore, association of IVF
with GDM may develop indirectly from the effects of IVF
therapy on body fat accumulation, or directly from the proce-
dure itself, through incompletely understood mechanisms. IVF
may also associate with increased risk of breast and ovarian
cancer post-IVF, although this association remains poorly de-
scribed and more studies are needed [19].
Risks of IVF treatment on fetal outcomes
Risk of congenital malformation was shown to associate with
IVF, especially with multiple pregnancies. Mixed reports exist
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regarding fetal outcomes of IVF. While some studies suggest
that IVF may predispose to intrauterine growth retardation,
fetal anomalies, birth defect, and perinatal mortality [20, 21],
others show no difference in fetal outcomes between sponta-
neous and IVF-conceived pregnancies [22, 23]. In one study,
it was shown that IVF-conceived children are predisposed to
obesity, insulin resistance, type 2 diabetes mellitus (T2D), and
cardiovascular disease in adulthood [24]. Further prospective
studies are required to clarify adverse effects of IVF on off-
spring, regarding both fetal development and longer term ef-
fects that manifest in adulthood.
Does IVF therapy influence glucose
homeostasis?
During early pregnancy, fasting plasma glucose level is simi-
lar to that of non-pregnant women and usually remains con-
stant throughout pregnancy. However, although the level of
fasting serum insulin is similar to that in non-pregnant women
during the first trimester, fasting serum insulin levels increase
significantly during the second and third trimesters [25].
Insulin action is also 50–70% lower (measured by
hyperinsulinemic-euglycemic glucose clamp technique) dur-
ing the second and third trimesters compared with the first
trimester [26]. Insulin resistance drives increases in serum
insulin during mid-pregnancy, reflected by increases in the
homeostatic model assessment of insulin resistance
(HOMA-IR), and decreases in the quantitative insulin-
sensitivity check index (QUICKI) [25]. The diabetogenic ef-
fect of pregnancy stems from impairment of insulin sensitiv-
ity, and increased beta-cell activity in response to a greater
requirement for insulin. This phenomenon occurs primarily
during the second trimester, or late gestation [27]. Although
insulin resistance plays an important role in the etiology of
numerous adverse outcomes during pregnancy (such as
GDM, preeclampsia, and miscarriage), the mechanisms impli-
cated remain incompletely understood [25].
Under normal physiological conditions, estrogen and pro-
gesterone (gestational or maternal hormones) rise linearly dur-
ing pregnancy and play crucial roles in supporting pregnancy
and normal fetal development. Gestational hormones also
play important roles in insulin homeostasis. While estrogen
enhances insulin release and binding to its receptor, progester-
one actually reduces insulin binding to its receptor and hence
impairs glucose transport. Therefore, the diabetogenic effect
of pregnancy relates to the rise in serum levels of these hor-
mones along with the other placental-related (including
lactogen, human chorionic gonadotrophin (HCG), human pla-
cental lactogen, growth hormone, and cortisol), which results
in reduced insulin sensitivity, hyperinsulinemia, and impair-
ment of “pre-implantation environmental state” [27, 28].
Studies on oral contraceptive therapies (estrogen and proges-
terone combination) report different findings in relation to their
impact on glucose metabolism and insulin homeostasis.
Impairment in insulin sensitivity and glucose tolerance was com-
monly experienced with the use of oral contraceptives and evi-
denced by higher glucose and insulin levels [29, 30].While some
research findings suggest that insulin resistance is induced by
progesterone, others suggest that this is likely estrogen-related,
and that progesterone only affects the half-life of insulin [31, 32].
Given that the dose of gestational hormones administered with
IVF is higher than that used for combined oral hormonal contra-
ception, it is not possible to extrapolate glycemic and metabolic
effects of such therapies to those used for IVF. Interestingly, in
mice models, IVF associates with glucose intolerance [33].
However, human data is severely limited in relation to the effects
of IVF on insulin and glucose homeostasis during early pregnan-
cy. Further studies are required to explore the potential for IVF-
related hormonal therapies to augment the diabetogenic effect of
pregnancy. Such data will likely provide further insight into early
predictors of GDM.
Does IVF therapy increase maternal
cardiovascular and inflammatory risks?
The pregnancy-related inflammatory response is induced by
physiological and hormonal changes, and detectable as early as
embryo implantation [34]. Gestational hormones play an impor-
tant role in the synthesis of inflammatory markers [35]. C-
reactive protein (CRP), one of the commonly measured inflam-
matory markers, appears to increase with use of oral contracep-
tives, mainly in women below 35 years [36]. Based on this
observation, it is hypothesized that IVF-related treatments may
also stimulate an inflammatory response [34]. Increased serum
levels of high-sensitivity CRP (hs-CRP), a more precise CRP
assay of inflammation, has also been reported with increased
age andBMI, factors that both associate with infertility, and often
present in those seeking IVF treatments [37]. Furthermore, obe-
sity associates with inflammation and is itself often an indepen-
dent cardiovascular risk factor in obese women who use oral
contraceptive therapies.
In addition to inflammatory response, pregnancy also induces
changes in lipid and lipoprotein metabolism, usually evident fol-
lowing the first trimester. While some studies report an increase
in all lipid parameters during pregnancy [38, 39], others show
only a significant increase in triglycerides (TG) and very-low-
density lipoprotein (VLDL), and a decrease in low-density lipo-
protein (LDL) [40]. Impairment in the maternal lipid profile may
predispose to pregnancy-induced hypertension, preeclampsia
and GDM, and fetal macrosomia and cardiovascular diseases
[39]. Hypertriglyceridemia results from pregnancy-related in-
creased body fat and lipolytic activity, required to support preg-
nancy and in preparation for breastfeeding [41].
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Studies on the effects of oral contraceptive therapies on
lipid profile report conflicting data with regard to changes in
LDL level, but consistent data regarding increased TG levels
[29, 42]. Elevated estrogen level triggers hepatic synthesis of
lipids, with increased serum levels of TG and total cholesterol
(T-Chol) [38, 43]. Therefore, hypertriglyceridemia is thought
to be estrogen dose-related [28]. The literature is deficient
regarding reported data on the effect of IVF hormonal thera-
pies on lipid profile, and whether the latter augments the ath-
erogenic nature of pregnancy.
Does IVF therapy influence the gut
microbiome?
The relationship between intestinal microbiota and metabolic
health is very topical and of much interest. Changes in the gut
microbiota may influence the development of much twenty-
first century chronic illness, including diabetes mellitus, car-
diovascular disease, and dyslipidemia [44]. The gut microbi-
ota influences chronic inflammatory effects through media-
tion of leakiness of the gut lining [45]. A useful serum marker
for this process is lipopolysaccharide-binding protein (LBP),
an acute-phase protein. LBP binds bacterial compounds, in-
cluding lipopolysaccharides (LPS), an outer membrane com-
ponent of gram-negative bacteria that normally reside within
the gut and form the microbiota. While strongly correlated
with obesity, LBS is also negatively associated with insulin
sensitivity [46, 47]. The presence of LPS (also called endo-
toxins) in the gut is a normal physiological phenomenon, but
can become problematic when it crosses over a leaky gut wall
into the circulation. Gut wall permeability (with leakage of
LPS into the bloodstream) is likely influenced by stress, in-
cluding a high fat/energy-dense diet, or use of hormonal ther-
apies. This can result in “metabolic endotoxemia” [48, 49].
High levels of serum LBP strongly correlate with LPS and
associate with insulin resistance, obesity, and T2D [46].
In pregnancy, gut microbiota experiences a reduction in spe-
cies count and flora diversity from early to late, which may
predispose to gestational inflammation and metabolic impair-
ments. Given that body fat increases and insulin sensitivity
decreases throughout pregnancy, this in turn may impact the
immune system, inducing gut microflora disturbances [50].
Gut flora dysbiosis is associated with pregnancy-related com-
plications, such as insulin resistance, preeclampsia, miscarriage,
intrauterine growth retardation, and preterm delivery.
There is likely a role for oral contraceptives in the develop-
ment of inflammatory bowel disease (Crohn’s disease and ulcer-
ative colitis) [51]. Furthermore, gastrointestinal side effects com-
monly occur with oral contraceptive therapies. Oral estrogen and
progesterone treatment has been shown to affect gut permeabil-
ity, LPS signaling and cytokines-mediated inflammatory diseases
[52, 53]. We speculate that changes in microflora, LBP, and LPS
levels may occur with IVF-related therapies, given the higher
dose of reproductive hormones used compared with oral contra-
ceptives, and the stress of the procedure.Mediation of the inflam-
matory effects of IVF therapies may occur through changes in
the microbiota and serum levels of LBP and LPS. Such effects
may extend throughout the IVF-conceived pregnancy. There are
currently no reported studies on the effects of IVF treatments and
IVF-related pregnancies on lipopolysaccharide markers (such as
LBP and LPS) and gut microbiota. Assessment of gut perme-
ability during pregnancy (through IVF and spontaneous concep-
tion) would form a novel focus for future research.
Does IVF therapy alter thyroid function?
Thyroid dysfunction impairs menstrual cyclicity, female fer-
tility, and pregnancy outcome, and is classified as the second
most common endocrine disorder in women of reproductive
age [6]. Impaired thyroid function predicts poor IVF fertiliza-
tion outcome, emphasizing the importance of treating abnor-
mal thyroid levels at the preconception stage [54].
Estrogen has a significant impact on thyroid-stimulating
hormone (TSH) secretion and thyroid gland activity. During
pregnancy, “estrogen dominance” interferes with thyroid me-
tabolism by stimulating hepatic thyroxine-binding globulin
secretion, thereby reducing levels of free thyroid hormones
[55]. There is also a suppression of serum TSH level through-
out pregnancy, with the lower normal level in the first trimes-
ter [56, 57]. Furthermore, there is an increase in serum beta
human chorionic gonadotrophin hormone during pregnancy
(β-HCG; pregnancy indicator hormone), the effect being par-
ticularly pronounced in twin pregnancies. β-HCG has stimu-
latory effects at the TSH receptor and may drive over-
production of thyroid hormones during pregnancy, and also
contribute to suppression of TSH production [58]. Recurrent
pregnancy loss, preterm birth, and placenta abruption have
been associated with high TSH level [6, 54].
Oral contraceptives and pregnancy alter thyroid function in
similar ways, probably through estrogenic effects. However,
although the mechanisms are similar, pronounced changes in
thyroid hormones occur in pregnancy compared with the use
of oral contraceptive therapies. The difference in magnitude of
thyroid effects between pregnancy and oral contraceptive ther-
apies likely relates to exogenous estrogen therapy having a
dose-dependent effect on increasing serum thyroxine-
binding globulin and total serum thyroxin levels in those with
normal thyroid function [43, 59].
Regarding IVF therapies, in addition to exogenous estro-
gen, gonadotrophin-releasing hormone (GnRH) is also admin-
istered, the latter having been reported to affect levels of thy-
roid hormones (likely through indirect stimulation of gonad-
otrophin release and increased production of estrogen) [60].
There is a lack of data in the current literature on thyroid status
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in IVF-conceived versus spontaneously conceived pregnan-
cies. Given the potential for cumulative effects of estrogen-
related thyroid dysfunction during IVF-conceived pregnan-
cies, this should be a focus for future research.
Conclusion
The increased risk of complications and adverse outcomes of
IVF-conceived pregnancies remain contentious. However, ma-
ternal preconception characteristics are likely to play a role.
This promotes the importance of screening high-risk popula-
tions at preconception, and early management of controllable
factors to prevent possible obstetric complications and predict
IVF success. The impact of pregnancy onmetabolic, endocrine,
and inflammatory parameters is well established. However,
similar data in IVF-conceived pregnancies are lacking.
Identifying early maternal metabolic and inflammatory bio-
markers during IVF therapy and IVF-conceived early pregnan-
cy may act as predictors for future maternal and fetal problems
during the ensuing pregnancy. Such predictive factors could
improve both pregnancy and fetal outcomes of IVF therapies.
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